Literature DB >> 33976413

Polygenic risk scores outperform other tests in AS.

Jessica McHugh1.   

Abstract

Year:  2021        PMID： 33976413     DOI： 10.1038/s41584-021-00630-1

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  1 in total

1.  Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y).

Authors:  Robert Bm Landewé; Lianne S Gensler; Denis Poddubnyy; Proton Rahman; Maja Hojnik; Xiaoqi Li; Soyi Liu Leage; David Adams; Hilde Carlier; Filip Van den Bosch
Journal:  Ann Rheum Dis       Date:  2021-05-06       Impact factor: 19.103
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.